300294 Stock Overview
Engages in the blood product businesses in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥30.50 |
| 52 Week High | CN¥41.98 |
| 52 Week Low | CN¥22.91 |
| Beta | 0.40 |
| 11 Month Change | -8.55% |
| 3 Month Change | -4.69% |
| 1 Year Change | -6.64% |
| 33 Year Change | -27.21% |
| 5 Year Change | -1.01% |
| Change since IPO | 253.74% |
Recent News & Updates
Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality
Nov 01
A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)
Oct 01Recent updates
Investors Can Find Comfort In China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Earnings Quality
Nov 01A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)
Oct 01Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings
Sep 12Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?
Jul 25China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark
Jun 12China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30
Apr 26Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?
Apr 22China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings
Apr 01What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates
Mar 31Shareholder Returns
| 300294 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -5.3% | -7.6% | -6.7% |
| 1Y | -6.6% | -19.7% | 1.9% |
Return vs Industry: 300294 exceeded the CN Biotechs industry which returned -19.7% over the past year.
Return vs Market: 300294 underperformed the CN Market which returned 1.9% over the past year.
Price Volatility
| 300294 volatility | |
|---|---|
| 300294 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.5% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 300294 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300294's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 1,444 | Xiaoming Liang | www.china-boya.com |
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. The company offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. It provides bone polypeptide, oxytocin, heparin sodium, and posterior pituitary injection products; and metformin hydrochloride enteric-coated tablets, glimepiride tablets, calcium dobesilate products, and pioglitazone hydrochloride dispersible tablets.
China Resources Boya Bio-pharmaceutical Group Co.,Ltd Fundamentals Summary
| 300294 fundamental statistics | |
|---|---|
| Market cap | CN¥15.38b |
| Earnings (TTM) | CN¥186.10m |
| Revenue (TTM) | CN¥1.71b |
82.6x
P/E Ratio9.0x
P/S RatioIs 300294 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300294 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.71b |
| Cost of Revenue | CN¥579.41m |
| Gross Profit | CN¥1.13b |
| Other Expenses | CN¥941.18m |
| Earnings | CN¥186.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.37 |
| Gross Margin | 66.05% |
| Net Profit Margin | 10.90% |
| Debt/Equity Ratio | 0.03% |
How did 300294 perform over the long term?
See historical performance and comparison